David S. Mendelson

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

Roy S. Herbst, S. Gail Eckhardt, Razelle Kurzrock et al. · Journal of Clinical Oncology · 2010 · 437 citations

Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer

David B. Agus, Michael S. Gordon, Charles Taylor et al. · Journal of Clinical Oncology · 2005 · 387 citations · Full text

A Roadmap for Foundational Research on Artificial Intelligence in Medical Imaging: From the 2018 NIH/RSNA/ACR/The Academy Workshop

Curtis P. Langlotz, Bibb Allen, Bradley J. Erickson et al. · Radiology · 2019 · 350 citations · Full text

Artificial Intelligence, Medical Image Segmentation, Engineering +29

Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study

Shanu Modi, Alison Stopeck, Michael S. Gordon et al. · Journal of Clinical Oncology · 2007 · 331 citations

Pulmonary Nontuberculous Mycobacterial Disease, Ontario, Canada, 1998–2010

Theodore K. Marras, David S. Mendelson, Alex Marchand‐Austin et al. · Emerging infectious diseases · 2013 · 217 citations · Full text